Arrowhead to Present Plozasiran Data in Chicago
Arrowhead Pharmaceuticals will present clinical data on plozasiran and ARO-DIMER-PA at the American Heart Association Scientific Sessions 2026 in Chicago.
Updated on Nov. 2, 2026 in Heart Disease
Arrowhead Pharmaceuticals will present three-year PALISADE data on plozasiran in a moderated poster session on Saturday, November 7, 2026, at the American Heart Association Scientific Sessions in Chicago. The company will also present a first-in-human trial of ARO-DIMER-PA and a pooled analysis of SHASTA-3 and SHASTA-4.
Why it matters
The presentations provide updated clinical data on plozasiran, which is not currently approved for severe hypertriglyceridemia, as the company prepares a supplemental new drug application for that indication. The data could inform how triglyceride-lowering therapies are evaluated for patients with elevated triglyceride levels.
The SHASTA-3 and SHASTA-4 studies randomized approximately 750 participants to 25 mg plozasiran or placebo, given once every three months over four doses. The presentation results and their comparison to placebo have not yet been released.
The players
Arrowhead Pharmaceuticals
A biopharmaceutical company listed on NASDAQ under the symbol ARWR, developing RNAi-based therapies including plozasiran.
American Heart Association
A leading U.S. nonprofit focused on cardiovascular health, which hosts the annual Scientific Sessions where major cardiology research is presented.
The details
Arrowhead will present a first-in-human trial of ARO-DIMER-PA, a dual-functional RNAi molecule designed to silence PCSK9 and APOC3 gene expression in liver cells, along with a pooled SHASTA analysis on triglyceride lowering and acute pancreatitis risk. A separate moderated poster will examine triglyceride reduction in patients using GLP-1 medications alongside plozasiran.
Timeline
December 2025: Plozasiran was granted Breakthrough Therapy designation for severe hypertriglyceridemia.
October 2026: Plozasiran entered the FDA Split Real Time Application Review pilot program.
Saturday, November 7, 2026, 9:15 a.m. CT: Moderated poster session on PALISADE three-year data.
Saturday, November 7, 2026, 3:15 to 4:30 p.m. CT: Oral presentations on ARO-DIMER-PA and the pooled SHASTA analysis.
Clinical Pipeline
The presentations extend the SHASTA-3 and SHASTA-4 Phase 3 program by adding pooled triglyceride and pancreatitis analysis and three-year PALISADE follow-up. This builds on the Breakthrough Therapy designation granted in December 2025 for severe hypertriglyceridemia.
Patients with elevated triglycerides should not expect changes to treatment options from these presentations alone, since plozasiran is not yet approved for severe hypertriglyceridemia. Anyone considering a triglyceride-lowering drug should discuss the current approved options with their clinician.
The takeaway
Triglyceride-lowering research is moving toward longer dosing intervals, with plozasiran given once every three months in trials. Patients should rely on approved treatments until new indications are authorized.
What happens next
Arrowhead's planned supplemental new drug application for plozasiran in severe hypertriglyceridemia is expected to follow the presentations, though no submission date has been announced.
Further reading
Explore more Heart Disease coverage from Chicago.
Source note: This article includes information reported by Firstwordpharma.
